Angiotensin-Converting Enzyme Inhibition Early After Heart Transplantation.

ABSTRACT:

Background

Cardiac allograft vasculopathy (CAV) remains a leading cause of mortality after heart transplantation (HT). Angiotensin-converting enzyme inhibitors (ACEIs) may retard the development of CAV but have not been well studied after HT.

Objectives

This study tested the safety and efficacy of the ACEI ramipril on the development of CAV early after HT.

Methods

In this prospective, multicenter, randomized, double-blind, placebo-controlled trial, 96 HT recipients were randomized to undergo ramipril or placebo therapy. They underwent coronary angiography, endothelial function testing; measurements of fractional flow reserve (FFR) and coronary flow reserve (CFR) and the index of microcirculatory resistance (IMR); and intravascular ultrasonography (IVUS) of the left an

SUBMITTER: Fearon WF 

PROVIDER: S-EPMC5546225 | biostudies-literature | 2017 Jun

REPOSITORIES: biostudies-literature